Who should manage germ cell tumours of the testis?

BJU International

Volumn 84, Issue 1, 1999, Pages 61-67

  Mead, G M ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

CLINICAL PROTOCOL; DOSIMETRY; DRUG FATALITY; DRUG TOXICITY; GERM CELL TUMOR; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; PRIORITY JOURNAL; REVIEW; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CANCER CARE FACILITIES; CISPLATIN; ETOPOSIDE; GERMINOMA; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS;

EID: 0032768641     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00141.x     Document Type: Review

References (40)

1. 1 Jones A, Fergus JN. Chapman J, Houghton L. Is surveillance for stage I germ cell tumours of the testis appropriate outside a specialist centre? BJU Int 1999; 84: 79-84
2. 2 Lee AHS, Mead GM, Theaker JM. The value of central histopathological review before treatment. Br J Urol 1999; 84: 75-78
3. 3 Expert Advisory Group on Cancer. A policy framework for commissioning cancer services: A Report by the Expert Advisory Group on Cancer to the Chief Medical Officer of England and Wales, 1995. Department of Health, London: HM Stationery Office, 1995
4. 4 Scottish Intercollegiate Guidelines Network. Management of adult testicular germ cell tumours. A national clinical guideline. Edinburgh: Royal College of Physicians, 1998
5. 5 Office for National Statistics MD, 1 97/1. 1998
6. 6 Warde P, Gospodarowicz MK, Panzarella T et al. Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 1995; 13: 2255-62
7. 7 Warde P, von der Maase H, Horwich A, Gospodarowicz M, Panzarella T, Specht L. Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 1998; 17: 309a
8. 8 Sharda NN, Kinsella TJ. Ritter MA. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 1996; 14: 2933-9
9. 9 Fossa SD, Horwich A, Russell JM. Roberts JT. Widmer B, Stenning SP on behalf of the MRC Testicular Tumour Working Party. Optimal field size in radiotherapy of seminoma stage I. A Medical Research Council (UK) randomised trial. J Clin Oncol 1999: in press
10. 10 van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW et al. Second cancer risk following testicular cancer: A follow up study of 1,909 patients. J Clin Oncol 1993; 11: 415-24
11. 11 Read G. Johnston RJ. Short duration radiotherapy in stage I seminoma of the testis: Preliminary results of a prospective study. Clin Oncol 1993; 5: 364-6
12. 12 Oliver RTD, Edmonds PM, Ong JYH et al. Pilot studies of 1 and 2 course carboplatin as adjuvant for stage I seminoma. Should it be tested in a randomised trial against radiotherapy? Int J Rad Oncol Biol Phys 1994; 29: 2-8
13. 13 Warde P, Gospodarowicz M, Panzarella T et al. Management of stage II seminoma. J Clin Oncol 1998; 16: 290-4
14. 14 Horwich A, Oliver RTD, Fossa SD, Wilkinson P, Mead GM, Stenning SP on behalf of the UK MRC Testicular Tumour Working Party. A randomised MRC trial comparing single agent carboplatin (Ca) with the combination of etoposide (E) and cisplatin (P) in patients (pts) with advanced metastatic seminoma. Proc Am Soc Clin Oncol 1996; 15: 668
15. 15 Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-8
16. 16 Freedman LS, Parkinson MC, Jones WG et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 4: 2, 194-297
17. 17 Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I non-seminomatous germ cell tumours of the testis; A Medical Research Council Report. J Clin Oncol 1996; 14: 1106-13
18. 18 Dearnaley DP, Foss SA, Kaye SB et al. Adjuvant bleomycin. vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT) -A Medical Research Council (MRC) Pilot Study. Proc Am Soc Clin Oncol 1998; 17: 1188
19. 19 International Germ Cell Cancer Collaborative Group. International germ cell consensus classification; a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
20. 20 Williams SD, Birch R, Einhorn LH, Irwin L. Greco AF, Loehrer PJ. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40
21. 21 de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomised study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15: 1837-43
22. 22 Horwich A, Sleijfer DT, Fossa SD et al. Randomised trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitional Medical Research Council/European Organisation for Research and Treatment of cancer trial. J Clin Oncol 1997; 15: 1844-52
23. 23 Saxman SB, Finch D, Gonin R, Einhorn H. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favourable-prognosis germ-cell tumours. The Indiana University experience. J Clin Oncol 1998; 16: 702-6
24. 24 Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumour: a randomised Medical Research Council/European Organisation for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701
25. 25 Fossa SD, Kaye SB, Mead GM et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 1998; 16: 716-24
26. 26 Kirk D. Workshop on surgery for metastatic disease. In Jones WG, Appleyard I, Harnden P, Joffe JU. eds, Germ Cell Tumours. IV ed. London: John Libbey & Co. 1998
27. 27 van der Maase H, Rorth M, Walbom Jorgenson S et al. Carcinoma in situ of the contralateral testis in patients with testicular germ cell cancers. Study of 27 cases in 500 patients. Br Med J 1986; 293: 1398-401
28. 28 Dieckmann K-P, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996; 14: 3126-32
29. 29 Wanderas EH, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 1997; 33: 244-52
30. 30 Harland SJ, Cook PA, Fossa SD. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol 1998; 160: 1353-7
31. 31 Stiller C. Survival of patients with cancer. Those included in clinical trials do better. Br Med J 1989; 299: 1058-9
32. 32 Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-62
33. 33 Aass N, Klepp O, Cavallin-Stahl E et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicentre experience. J Clin Oncol 1991; 9: 818-26
34. 34 Norum J. Nordoy T, Wist E. Testicular cancer treated in a minor general oncology department. Eur J Cancer 1995; 31A: 293-5
35. 35 Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 1993; 341: 999-1002
36. 36 Howard GCW, Clarke K, Elia MH et al. A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. Br J Cancer 1995; 72: 1303-6
37. 37 Howard GCW, Clarke K, Elia MH et al. A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. Br J Cancer 1995; 72: 1307-11
38. 38 Feuer EJ, Frey CM, Brawley OW et al. After treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994; 12: 368-77
39. 39 Collette L, Sylvester RJ, Stenning SP et al. The impact of the treating institution on survival in poor prognosis metastatic non-seminoma. In Jones WG, Appleyard I, Harnden P, Joffe JU, eds, Germ Cell Tumours, IV edn. London: John Libbey & Co, 1998
40. 40 Loughrey GJ, Carrington BM, Anderson H, Dobson MJ, Lo Ying Ping F. Review of outside cross-sectional imaging by oncological radiologists: does it make a difference? Br J Radiol 1999; 54: 149-54